ProfileGDS5678 / 1441913_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 67% 66% 65% 63% 65% 68% 67% 67% 65% 65% 66% 65% 66% 66% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 14.059167
GSM967853U87-EV human glioblastoma xenograft - Control 23.9771766
GSM967854U87-EV human glioblastoma xenograft - Control 33.9323165
GSM967855U87-EV human glioblastoma xenograft - Control 43.7423563
GSM967856U87-EV human glioblastoma xenograft - Control 53.9013665
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.2018168
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.1302867
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 34.0981167
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.9246265
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.9253265
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.954866
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.8963665
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 44.0082666
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.9654966